Opendata, web and dolomites

NOVOBIOME-1 SIGNED

Development of a novel human derived probiotic species platform - Phase 1

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOVOBIOME-1 project word cloud

Explore the words cloud of the NOVOBIOME-1 project. It provides you a very rough idea of what is the project "NOVOBIOME-1" about.

segment    house    generation    b2b    facilities    first    dutch    commercializing    infrastructure    full    sold    million    worldwide    probiotic    coming    untapped    winclove    maximize    8m    ngps    cycle    anticipates    radically    tackle    successful    technological    human    commercialization    track    moving    leader    company    reached    sustainable    14    cultivation    platform    annum    mainly    130    models    flourishing    ngp    intrinsic    struggling    countries    2018    companies    generate    limited    25    techniques    market    73    biotherapeutic    service    clients    healthy    live    successfully    positive    daily    fee    functional    substantially    35    provides    global    microbiota    timeline    fte    manufacturing    customers    novobiome    combines    dosages    formulations    innovative    lbps    leverages    play    anticipated    services    business    probiotics    whereas    attractive    origins    instrument    turnover    sme    fast    grow   

Project "NOVOBIOME-1" data sheet

The following table provides information about the project.

Coordinator
WINCLOVE BV 

Organization address
address: HULSTWEG 11
city: AMSTERDAM
postcode: 1032 LB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WINCLOVE BV NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

The global probiotics market is flourishing and anticipated to grow substantially in the coming years due the highly promising application of next-generation probiotics (NGPs) as live biotherapeutic products (LBPs). Whereas traditional probiotics are mainly derived from non-human origins with limited positive effects, NGPs are human-derived and play a key role in a healthy microbiota. All major probiotic companies are now moving into this field, however they are struggling with product development due to the intrinsic properties of NGPs. As a result, no NGP products have successfully reached the market yet. NGP product development requires radically new techniques for cultivation and production. This untapped market segment is highly attractive for Winclove. To tackle this problem, Winclove is developing the NOVOBIOME platform – covering the full cycle of NGP product development. Winclove’s approach leverages its already functional in-house facilities and infrastructure and combines it with innovative models and technological methods that can fast-track the timeline of NGP product to market for our clients. Winclove, an innovative Dutch SME, is a leader in microbiota-management, which has been offering services in research, development and manufacturing of probiotic formulations for over 25 years. Winclove has been very successful in growing the company into a sustainable business with 73 FTE, growing 14% per annum on average. It provides its services to over 80 customers in 35 countries worldwide. As such, it has sold via its clients over 130 million daily dosages in 2018. Winclove aims to provide the NOVOBIOME platform as a B2B fee for service to dedicated innovative companies that are working on NGP-based LBPs. Winclove anticipates to generate €8M in turnover within the first 5 years of commercializing the NOVOBIOME platform. This SME-1 instrument project NOVOBIOME phase 1 enables Winclove to investigate the requirements to maximize the European commercialization

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVOBIOME-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVOBIOME-1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More